Familial hemophagocytic lymphohistiocytosis in a neonate
Case report and literature review
Yue Yang, MS\textsuperscript{a}, Zebin Luo, MD\textsuperscript{b}, Tianming Yuan, MD\textsuperscript{a,*}

Abstract
Rationale: Familial hemophagocytic lymphohistiocytosis (FHL) is a potentially fatal disease that rarely presents in the neonatal period. Timely diagnosis is a key challenge owing to the atypical clinical manifestations. Here, we describe a case of FHL type 3 with disease onset in the early neonatal period and review the relevant literature. Our findings may provide insights into the diagnosis and treatment of this rare disease.

Patient concerns: A 6-day-old male neonate presented with fever, hepatosplenomegaly, cytopenia, hyperferritinemia, hypofibrinogenemia, hemophagocytosis, and hypertriglyceridemia.

Diagnosis: Considering the clinical picture (prolonged fever, progressive hepatosplenomegaly, high triglycerides, low fibrinogen, and high ferritin), along with abnormal natural killer-cell activity, combining sequence analysis of genomic DNA results (compound heterozygous mutations of UNC13D), the patient was finally diagnosed with FHL type 3 (FHL3).

Interventions: The patient was initially treated with HLH-1994 protocol and subsequently switched to an oral regimen of ruxolitinib due to incomplete remission of the disease.

Outcomes: The trend of change in weekly cytokine levels, neutrophil counts, hemoglobin, and platelet counts indicated that the complete remission was not achieved after the treatment of HLH-1994 protocol. The platelet counts fluctuated within the normal range after oral administration of ruxolitinib. But soon after, the patient did not respond to treatment and eventually died of respiratory failure.

Lesson: Timely diagnosis of FHL is challenging. This case report illustrates that thrombocytopenia can be the first clinical sign of FHL with neonatal onset. Genetic testing, detection of cytokines, and flow cytometry should be performed as soon as possible to confirm the diagnosis. Given the high morbidity and mortality of FHL, pediatricians should have a high suspicion index for this disease.

Abbreviations: DOL = day of life, FHL = familial hemophagocytic lymphohistiocytosis, HSCT = hematopoietic stem cell transplantation, HLH = hemophagocytic lymphohistiocytosis, IFN = interferon, IL = interleukin, NK = natural killer, VP-16 = etoposide, WBC = white blood cell.

Keywords: case report, cytokines, familial hemophagocytic lymphohistiocytosis, hemophagocytic lymphohistiocytosis, neonatal thrombocytopenia

1. Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal disease characterized by dysregulated immune response to antigens, resulting in uncontrolled activation of immune cells and life-threatening cytokine storm.\cite{1,2} HLH presents in a variety of clinical contexts and with multiple etiologic associations. HLH can be categorized into 2 types: primary and secondary. The term “primary HLH” often refers to patients with clear familial inheritance or genetic causes. Patients in the “secondary HLH” category are those associated with infections, autoimmune disease, or underlying malignancy.\cite{3} The main clinical manifestations are fever, hepatosplenomegaly, and cytopenia, while some patients may exhibit central nervous system involvement.\cite{2} Although HLH can occur in all age groups, neonatal onset is rare, accounting for only 4% of all HLH cases.\cite{4} Autosomal recessive inheritance is a common mode of inheritance of this disease [also known as familial hemophagocytic lymphohistiocytosis (FHL)]. Most children with FHL are born healthy and develop the illness in the first 2 to 6 months of life.\cite{5} FHL with onset in the neonatal period is rare. Here, we describe a case of FHL type 3 with disease onset in the early neonatal period and review the relevant...
literature. Our findings may provide insights into the diagnosis and treatment of this rare disease.

2. Case presentation

A 6-day-old male neonate was referred to the neonatal department of our hospital on November 30, 2019 because of moaning and rash since the last 5 days. He was delivered by elective caesarean section at a local hospital (gestational age: 40 weeks; birth weight: 4100g). Apagar scores at 1 and 5 minutes were both 10. His parents denied close consanguineous marriage. The patient started moaning and exhibited shortness of breath after birth, with pinkish unfading rash after pressing on face; there was no history of fever.

At the local hospital, blood routine (day of life [DOL] 1) examination showed normal white blood cell (WBC) count (7.2 x 10^9/L), neutrophil count (4.12 x 10^9/L), and hemoglobin level (140g/L); however, he had severe thrombocytopenia (27 x 10^9/L). Chest x-ray (DOL1) showed inflammatory changes in both lower lung fields. With a presumptive diagnosis of neonatal pneumonia and thrombocytopenia, he was treated with penicillin, cephalosporin, vitamin K1, dexamethasone, intravenous immunoglobulin, platelet transfusion, and oxygen inhalation. After treatment, his respiratory symptoms were alleviated; however, the platelet count was still in the range of 10 to 47 x 10^9/L.

Subsequently, he was admitted to our neonatal department on DOL6 for further management due to persistent thrombocytopenia. On physical examination, his body temperature was 37.5°C; liver was palpable at 2 cm below the rib edge, while spleen was not palpable; pressing on the face resulted in a pinkish unfading rash. On DOL9, he developed supraventricular tachycardia, which responded to treatment with propafenone. Blood routine examination (1 hour after admission at our hospital) showed decreased WBC (5.53 x 10^9/L), neutrophils: 0.17 x 10^9/L, hemoglobin: 69g/L, platelet count: 8 x 10^9/L), increased ferritin (>1500mg/L), decreased fibrinogen (0.95g/L), high triglycerides (4.81 mmol/L), and elevated cytokines (interferon [IFN]-γ: 73.6 pg/mL; interleukin [IL]-10: 1081.9 pg/mL; and IL-6: 100.1 pg/mL). Considering the clinical picture (prolonged fever, progressive hepatosplenomegaly, high triglycerides, low fibrinogen, and high ferritin), which qualified 5 out of the 8 HLH-2004 criteria,[6] the diagnosis of HLH was confirmed and the patient was transferred to the hematology department for supportive treatment with HLH-1994 protocol. Subsequent natural killer (NK) cells stimulation test showed severe dysregulation of immune response (Fig. 1). Sequence analysis of genomic DNA from his blood sample revealed compound heterozygous mutations of UNC13D gene: c.1055+1G>A in exon12 (pathogenetic mutation) and c.118-308C>T in intron (likely pathogenetic mutation). Genetic testing of parents confirmed that the mutation c.1055+1G>A in exon12 was inherited from his father and c.118-308C>T in intron from his mother (Figs. 2 and 3). Based on the above results, the patient was finally diagnosed with FHL type 3 (FHL3).

---

**Figure 1.** Severely decreased ΔCD107a in NK cells of the patient. The expression of CD107a in NK cells is 0.66% prior to stimulation and 2.07% poststimulation; thus, ΔCD107a is 1.41% (ΔCD107a >10% indicates normal degranulation function). NK = natural killer.
The patient was discharged on January 5, 2020 and followed up in the hematology department with weekly etoposide (VP-16) infusion and adjustment of dexamethasone dose according to the HLH-1994 protocol. The trend of change in cytokine levels, neutrophil counts, hemoglobin, and platelet counts since the onset of HLH are shown in Table 1. Laboratory examination after 8 weeks of standard chemotherapy showed normal WBC count (8.15 × 10^9/L), neutrophil count (1.85 × 10^9), thrombocytopenia (67 × 10^9/L), low fibrinogen (1.55 g/L), high triglycerides (5.06 mmol/L), and normal cytokine levels (IFN-γ: 3.3 pg/mL, IL-10: 43.3 pg/mL, IL-6: 12.2 pg/mL). Spleen was still 3.6 cm below the ribs. These findings indicated that complete remission was not achieved. Subsequently, he was prescribed oral ruxolitinib. The platelet counts fluctuated within the normal range for some time. However, the patient presented again with fever (37.9°C) and hypercytokinemia (IFN-γ: 58.6 pg/mL; IL-10: 260.3 pg/mL; IL-6: 17.5 pg/mL) on March 30, 2020. The patient did not respond to treatment and eventually died of respiratory failure.

3. Literature review and discussion
HLH is a potentially life-threatening pathological immune activation syndrome characterized by functional defects of cytotoxic T lymphocytes and NK cells. HLH patients develop systemic inflammation due to uncontrolled production of inflammatory cytokines and macrophage activation.[7] HLH is

| Day of life (DOL) | Neutrophil (1.5–7.8) | Hemoglobin (110–155) | Platelet (100–400) | IL-10 (2.6–4.9) | IFN-γ (1.6–13.7) | IL-6 (1.7–16.6) |
|------------------|----------------------|----------------------|-------------------|----------------|----------------|----------------|
| 6                | 0.78                 | 110                  | 36                |                |                |                |
| 19               | 0.17                 | 100                  | 8                 | 1081.9         | 73.6           | 100.1          |
| 46               | 2.93                 | 96                   | 560               | 51.1           | 5.1            | 4.4            |
| 84               | 1.85                 | 88                   | 67                | 43             | 3.3            | 12.2           |
| 98               | 2.41                 | 96                   | 425               |                |                |                |
| 113              | 0.25                 | 81                   | 113               | 280.3          | 58.6           | 17.5           |
| 119              | 0.96                 | 97                   | 105               | 79.8           | 34.8           | 6.3            |
| 129              | 1.23                 | 55                   | 193               | 365.8          | 110.3          | 4.9            |
| 136              | 0.57                 | 81                   | 71                | 82.6           | 510            | 22.6           |
| 143              | 2.54                 | 49                   | 117               | 562.5          | 44.3           | 17.6           |
| 147              | 4.48                 | 100                  | 8                 |                |                |                |
| 155              | 1.74                 | 65                   | 60                | 10.8           | 12.8           | 7.5            |
| 159              | 2.4                  | 51                   | 5                 |                |                |                |
| 163              | 0.89                 | 117                  | 13                | 25.6           | 24.5           | 9.3            |
| 171              | 9.82                 | 92                   | 11                |                |                |                |

IL-10 = interleukin-10, IFN-γ = interferon-γ, IL-6 = interleukin-6.
categorized into 2 types: primary or secondary. It can be inherited or may occur secondary to infections, autoimmune disease, or underlying malignancy. There is a lack of nationwide data in China, and the literature reports mainly pertain to secondary HLH. In a multicenter retrospective study by Xu et al., the median age of children (n = 323) at diagnosis of HLH was 2.2 years. With an incidence of approximately 1:50,000 to 1:300,000 live births, most children with FHL are born healthy and develop symptoms within the first 2 to 6 months of life, although it can occur in all age-groups, neonatal onset is rare, accounting for only 4% of all HLH cases.

Here, we reviewed 9 cases of neonate FHL (onset within 28 days after birth) (Table 2). This table shows the clinical and laboratory features of 9 infants. These cases were all identified as FHL because of positive family history or the discovery of related gene mutations. Four cases were FHL type2, 2 cases were FHL type5, only 1 case was FHL type3, and the other 2 cases did not find the specific gene mutations. As we can see, neonatal HLH has an atypical presentation, fever, hepatosplenomegaly, and thrombocytopenia were almost consistently found in all cases. In some cases, non-specific initial clinical symptoms such as non-immune hydrops and fetal distress are the only manifestation.

Therefore, timely diagnosis of neonatal HLH is typically challenging, especially in infants with fever and thrombocytopenia. Neonatal thrombocytopenia is a common problem in all infants. As the diagnostic criteria for HLH include cytopenia, HLH should be considered in infants with thrombocytopenia, especially in those presenting with multiple organ involvement or elevated cytokine levels. In a retrospective analysis of 124 children with FHL, thrombocytopenia was observed in all patients. Fever of unknown reason is another common clinical manifestation of HLH, which needs to be differentiated from that caused by secondary infection. Clinically, extremely elevated IL-6 levels (>1000 pg/mL) and slightly elevated IFN-γ are mostly seen in sepsis caused by gram-negative bacteria. On the contrast, Xu et al. found that in the acute phase of HLH, the levels of IFN-γ and IL-10 were significantly increased, while those of IL-6 were only moderately increased, the same cytokine changes were found in the fourth case in Table 2. Cytokine profile can be an important biomarker for monitoring HLH status, which can allow for earlier diagnosis and institution of more effective treatment.

### Table 2

| No. | Study                | Age of onset | Symptoms and signs                  | Laboratory examination                                      | Gene mutation                                     | Treatment                      | Outcomes |
|-----|----------------------|--------------|-------------------------------------|-------------------------------------------------------------|---------------------------------------------------|--------------------------------|----------|
| 1   | Roganovic et al (2010) | 1DOL         | Respiratory distress, jaundice, fever, hepatosplenomegaly, subcutaneous nodules | Thrombocytopenia, anemia, high ferritin, hypofibrinogenemia | Not found                                        | HLH-04 protocol               | Died     |
| 2   | Jain et al (2012)     | 21DOL        | Fever, hepatosplenomegaly, abdominal distension, lethargy | Thrombocytopenia, anemia, high ferritin, hypofibrinogenemia, hypertriglyceridemia | c.1697G>A mutation in STXB2 gene                  | Dexamethasone, CsA             | Died     |
| 3   | Chia et al (2012)     | 1DOL         | Fever, hepatosplenomegaly, ascites | Cytopenia, high ferritin, elevated liver enzymes, hypofibrinogenemia | c.145G>A in exon2 and c.[853_855delAAAG] in exon3 in PRF1 gene | HLH-04 protocol               | Died     |
| 4   | Chen et al (2013)     | 8DOL         | Fever, hepatosplenomegaly, petechia | Thrombocytopenia, high ferritin, hypofibrinogenemia, hypertriglyceridemia, low perforin expression, degranulation defect of NK cells, increased IFN-γ and IL-10 | c.2295_2298delGCAG, p.Glu765Aspfs*27 mutations in exon 23 of UNC13D gene | HLH-04 protocol               | Died     |
| 5   | Greenhalgh et al (2015) | 1DOL        | Respiratory distress, abdominal distension, hepatosplenomegaly, jaundice, seizure, hypotension, hyperglycemia | Thrombocytopenia, anemia, high ferritin, elevated liver enzymes | Compound heterozygous-ity mutations in PRF1 gene | Blood transfusion               | Died     |
| 6   | Hinson et al (2015)   | 1DOL         | Petechia, hepatosplenomegaly, edema, fever, scleral icterus, silvery hair, generalized edema | Thrombocytopenia, elevated liver enzymes, high ferritin, elevated sIL2r | Allele 1:272C>T (A91V) in PRF1 gene              | HLH-04 protocol, blood transplant | Alive    |
| 7   | Zarrini et al (2017)  | 2DOL         | Respiratory distress, fever, hepatosplenomegaly, jaundice | Cytopenia, high ferritin, elevated liver enzymes, hypofibrinogenemia, hypertriglyceridemia | Not found                                        | HLH-04 protocol               | Died     |
| 8   | Sato et al (2020)     | 18DOL        | Fever, hepatosplenomegaly, petechia | Cytopenia, elevated liver enzymes, hypofibrinogenemia | c.781G>A (p.E261K) and c.1491T>A (p.C497*) in exon 3 of PRF1 gene | Prednisolone                   | Died     |
| 9   | Benavides et al (2020) | 1DOL        | hepatosplenomegaly               | Hyperbilirubinemia, thrombocytopenia, anemia, high ferritin, elevated sIL2r, elevated liver enzymes, degranulation defect of NK cells | c.568C>T (p.Arg190Cys) in exon 7 of STXB2 gene | Dexamethasone, VP-16, CsA | Alive    |

CsA = cyclosporine A, Dexamethasone, DOL = day-of-life, HLH = hemophagocytic lymphohistiocytosis, IFN-γ = interferon-γ, IL-10 = interleukin-10, NK = natural killer, VP-16 = etoposide.
the disease was in remission. However, the patient presented again with fever, pulmonary pneumocystis, elevated IFN-γ and IL-10, which resulted from the re-activation of HLH (Table 1). There are many genetic causes of HLH susceptibility. The cause of FHL type 1 remains unclear. FHL types 2 to 5 are due to mutations in PRF1, UNC13D, STX11, and STXBPD, respectively. PRF1 and UNC13D mutations were the most common mutations in Chinese children with FHL. The protein products of these genes play an important role in normal cytotoxic granule exocytosis. In FHL patients, granules contents (containing perforin and granzymes) will not be released into the immune synapse, and the target cells will not be killed. FHL type 3 (FHL3) is caused by a mutation in the UNC13D gene encoding Munc13-4 protein, located in 17q25. Till date, at least 112 different mutations in UNC13D have been reported as the cause of FHL3: 60 missense/non-sense, 25 splicings/regulatory, 25 deletion/insertion mutations, and 2 complex gene rearrangements. The possibility of a potential genetic diagnosis is highest in infants. In a study of Chinn et al., 61% of patients below the age of 1 year were found to have a genetic HLH disease. Gene testing of our patient showed that the UNC13D gene carried a compound heterozygous mutation, from father and mother (respectively), which has been reported as a pathogenic mutation site in the past.

Other than mutation analysis, flow cytometric measurements are also important to further verify the pathogenetic effect of gene mutation. The results of our patient showed that the cytotoxicity of NK cells was normal; and the expression of CD107a was greatly decreased, which was consistent with the flow cytometry results in patients with FHL3. However, due to incomprensive medical technology and the rapid development of the patient’s condition, the detection of NK cells degranulation function failed to start in time in most cases. As shown in Table 2, 4 patients received HLH-2004 protocol, but only 2 patients survived after treatment, indicating a high mortality rate of neonate HLH. The prognosis for HLH infants is poor if untreated. A commonly used treatment approach consists of dexamethasone and VP-16 based on the experiences of the Histiocyte Society HLH-1994 and HLH-2004 studies. Our patient did not achieve complete remission after 8 weeks of application of the HLH-1994 protocol, which suggested that the disease was still in active stage. Notably, some novel treatment regimens have been reported to further improve the efficiency of treatment. A retrospective study suggested that alemtuzumab therapy of refractory HLH resulted in improvement and survival to allogeneic hematopoietic stem cell transplantation (HSCT) in most patients. In the study of Bami et al., initial treatment with anakinra is a feasible treatment alternative for patients with secondary HLH and may allow for avoidance of VP-16. Wang et al. reported a response rate up to 75% in refractory HLH achieved by using the liposomal doxorubicin treatment combined with VP-16 and methylprednisolone as salvage therapy. Emapalumab was an efficacious targeted therapy for patients with primary HLH, Franco et al. found that across all patients treated with emapalumab (n = 34), the overall response rate at the end of treatment was 64.7%. Our patient was treated with oral ruxolitinib as a second-line treatment, and the platelet counts fluctuated within the range of 300 to 500 × 10⁹/L for some time. Ruxolitinib is a safe and effective salvage therapy that alleviates HLH symptoms by reducing cytokine levels and increases the possibility of refractory/recurrent HLH patients receiving HSCT or treatment for underlying diseases. Consequently, a multicenter, non-randomized trial to investigate the efficacy of ruxolitinib combined with the doxorubicin-etoeposide-methylprednisonolone regimen as a salvage therapy for refractory/relapsed HLH is underway in China. In most cases of FHL, immune-chemotherapy can temporarily control the disease; however, the disease is eventually fatal unless HSCT is performed. Unfortunately, our patient presented with pneumocystis, which resulted in respiratory failure, cardiac arrest, and other serious complications prior to receiving HSCT.

4. Conclusion

We report an infant with FHL3 who presented with thrombocytopenia as the initial clinical symptom. FHL with onset during the neonatal period is associated with high mortality and morbidity. Prompt recognition and treatment are critical to increasing the likelihood of survival. Owing to the non-specific clinical symptoms of neonatal FHL, timely diagnosis and treatment are typically challenging. In most FHL infants, thrombocytopenia is the initial clinical manifestation, while other symptoms such as fever and elevation of cytokines appear as the disease progresses. Neonatal FHL can rapidly deteriorate and lead to death in the absence of timely treatment. Therefore, the possibility of FHL should be considered in newborns who develop worsening thrombocytopenia of unknown etiology. Detection of cytokine levels and NK cells degranulation function should be performed as soon as possible. In cases with high clinical suspicion of neonatal HLH, treatment should be initiated even if the results of genetic testing are awaited.

Author contributions

Conceptualization: Tianming Yuan, Zebin Luo.
Data curation: Tianming Yuan, Yue Yang, Zebin Luo.
Formal analysis: Yue Yang.
Funding acquisition: Tianming Yuan.
Resources: Tianming Yuan, Zebin Luo.
Supervision: Tianming Yuan.
Writing – original draft: Yue Yang, Zebin Luo.
Writing – review & editing: Tianming Yuan, Zebin Luo.

References

[1] Tang YM, Xu XJ. Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment. ScientificWorldJournal 2011;11:697–708.
[2] Xu XJ, Wang HS, Ju XL, et al. Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study. Pediatr Blood Cancer 2017;64.
[3] Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood 2011;118:4041–52.
[4] Lee NM, Yi DY, Yoon SW, Chae SA, Lim IS, Choi YS. Haemophagocytic lymphohistiocytosis in a preterm infant: a case report. J Pak Med Assoc 2018;68:127–9.
[5] Bechera E, Djoud F, de Saint Basile G, Bertrand Y, Pondardre C. Haemophagocytic lymphohistiocytosis with Munc13-4 mutation: a case of recurrent fatal hydrops fetalis. Pediatrics 2011;128:e251–4.
[6] Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.
[7] Al-Samkari H, Berliner N. Hemophagocytic lymphohistiocytosis. Ann Rev Pathol 2018;13:27–49.
[8] Whaley B. Familial hemophagocytic lymphohistiocytosis in the neonate. Adv Neonatal Care 2011;11:101–7.
[9] Isaacs H. Fetal and neonatal histiocytes. Pediatr Blood Cancer 2006;47:123–9.
Neonatal hemophagocytic lymphohistiocytosis – case report. Coll Antropol 2010;34:285–90.

Chia J, Thia K, Brennan A, et al. Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin. Blood 2012;119:1713–6.

Chen Y, Wang Z, Cheng Y, Tang Y. Novel mutations in the UNC13D gene carried by a Chinese neonate with hemophagocytic lymphohistiocytosis. Yonsei Med J 2013;54:1053–7.

Greenhalgh M, Chopra M, Graf N, Isaacs D, Evans N. Unusual cause of hyperbilirubinemia in a preterm baby. J Paediatr Child Health 2015;51:1226–7.

Hinson A, Owen W, Prose N, Parikh S, Thornburg C. Congenital hemophagocytic lymphohistiocytosis presenting as thrombocytopenia in a newborn. J Pediatr Hematol Oncol 2015;37:300–3.

Zarrini P, Mosayebi Z, Ramyar A, Dalili H. Hemophagocytic lymphohistiocytosis in a neonate: case report. Acta Med Iran 2017;55:63–6.

Sato H, Kawasaki N, Kawasaki M, et al. Three consecutive cases of familial hemophagocytic lymphohistiocytosis, including a case due to maternal uniparental disomy. J Pediatr Hematol Oncol 2020;42:819–21.

Benavides N, Spessott W, Sanmillan M, et al. STXBP2-R190C variant in a patient with neonatal hemophagocytic lymphohistiocytosis (HLH) and deficiency reveals a critical role of STXBP2 Domain 2 on granule exocytosis. Front Immunol 2020;11:545414.

Trizzino A, zur Stadt U, Ueda I, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet 2008;45:13–21.

Xu XJ, Tang YM, Zhao N, et al. Diagnostic significance of Th1/Th2 cytokine pattern in childhood hemophagocytic lymphohistiocytosis. Chin J Pediatr 2011;49:685–9.

Ma H, Zhang R, Zhang L, et al. Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China. Ann Hematol 2020;99:2255–63.

Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood 2020;135:1332–43.

Hiejima E, Shibata H, Yasumi T, et al. Characterization of a large UNC13D gene duplication in a patient with familial hemophagocytic lymphohistiocytosis type 3. Clin Immunol 2018;191:63–6.

Chinn IK, Eckstein OS, Peckham-Gregory EC, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood 2018;132:89–100.

Sieni E, Cetica V, Santoro A, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet 2011;48:343–52.

Degar B. Familial hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 2015;29:903–13.

Marsh R, Allen C, McClain K, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013;60:101–9.

Bami S, Vagrecha A, Soberman D, et al. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2020;67:e28581.

Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood 2015;126:2186–92.

Al-Salama ZT. Emapalumab: first global approval. Drugs 2019;79:99–103.

Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med 2020;382:1811–22.

Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica 2019;105:e210–2.

Wang J, Zhang R, Wu X, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol 2021;193:761–8.